癌症PET成像的进展

SCI

15 June 2023

Advances in PET imaging of cancer

（Nature reviews. Cancer , IF：69.8）

Schwenck J, Sonanini D, Cotton JM, Rammensee HG, la Fougère C, Zender L, Pichler BJ. Advances in PET imaging of cancer. Nat Rev Cancer. 2023 May 31. doi: 10.1038/s41568-023-00576-4. Epub ahead of print. PMID: 37258875.

Corresponding Author: Johannes Schwenck, Dominik Sonanini, Jonathan M. Cotton. Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University of Tübingen, Tübingen, Germany.e-mail: bernd.pichler@med.uni-tuebingen.de

Abstract 摘要  

Molecular imaging has experienced enormous advancements in the areas of imaging technology, imaging probe and contrast development, and data quality, as well as machine learning-based data analysis. Positron emission tomography (PET) and its combination with computed tomography (CT) or magnetic resonance imaging (MRI) as a multimodality PET-CT or PET-MRI system offer a wealth of molecular, functional and morphological data with a single patient scan. Despite the recent technical advances and the availability of dozens of disease-specific contrast and imaging probes, only a few parameters, such as tumour size or the mean tracer uptake, are used for the evaluation of images in clinical practice. Multiparametric in vivo imaging data not only are highly quantitative but also can provide invaluable information about pathophysiology, receptor expression, metabolism, or morphological and functional features of tumours, such as pH, oxygenation or tissue density, as well as pharmacodynamic properties of drugs, to measure drug response with a contrast agent. It can further quantitatively map and spatially resolve the intertumoural and intratumoural heterogeneity, providing insights into tumour vulnerabilities for target-specific therapeutic interventions. Failure to exploit and integrate the full potential of such powerful imaging data may lead to a lost opportunity in which patients do not receive the best possible care. With the desire to implement personalized medicine in the cancer clinic, the full comprehensive diagnostic power of multiplexed imaging should be utilized.

分子影像技术在成像技术、成像探针和对比度的发展、数据质量以及基于机器学习的数据分析等领域取得了巨大进步。正电子发射断层扫描（PET）及其与计算机断层扫描（CT）或磁共振成像（MRI）的结合，作为一个多模态PET-CT或PET-MRI系统，通过对单个患者的扫描提供了丰富的分子、功能和形态数据。尽管最近的技术有所进步和数十种疾病特异性对比和成像探针具有可用性，但在临床实践中，只有少数参数，如肿瘤大小或示踪剂平均摄取量被用于评估图像。多参数体内成像数据不仅是高度定量的，而且可以提供关于肿瘤的病理生理学，受体表达，代谢或形态和功能特征（例如pH，氧合或组织密度），以及药物的药效学特性的宝贵信息，以使用造影剂衡量药物的反应。它可以进一步定量映射和空间解析肿瘤间和肿瘤内异质性，为靶向特异性治疗干预肿瘤的弱点提供见解。未能充分利用和整合此类强大成像数据的全部潜力，可能会导致无法获得尽可能最好的医疗的患者失去机会。随着癌症诊所渴望实施个性化医疗，应当充分利用多重成像的综合诊断能力。